Advertisement

Journal of Gastroenterology

, Volume 54, Issue 11, pp 972–983 | Cite as

Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors

Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study
  • Toshihisa TakeuchiEmail author
  • Hitoshi Hongo
  • Tsuguhiro Kimura
  • Yuichi Kojima
  • Satoshi Harada
  • Kazuhiro Ota
  • Nozomi Takeuchi
  • Takao Noguchi
  • Takuya Inoue
  • Mitsuyuki Murano
  • Kazuhide Higuchi
Original Article—Alimentary Tract

Abstract

Background

Proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) leads to a clinical decline in the quality of life (QOL). Therefore, new treatment options are needed. We performed a multicenter, randomized, parallel-group exploratory trial to determine the efficacy of hangeshashinto (HST) in patients with PPI-refractory GERD.

Methods

We enrolled 78 patients with PPI-refractory GERD for standard PPI regimens for at least 4 weeks and randomly assigned patients to receive either a combination of usual dose of rabeprazole (10 mg/day) + HST (7.5 g/day; HST group) or a double dose of rabeprazole (20 mg/day; double-dose PPI group). The primary end points were the extent of improvement in FSSG (Frequency Scale for the Symptoms of GERD) score and the change over time in FSSG score.

Results

There was no significant difference in terms of the improvement degree of the FSSG score between the two groups. Although the total FSSG score and reflux syndrome score decreased significantly for both groups over time (p < 0.001), the acid-related dyspepsia (ARD) score decreased significantly in the HST group from 1 week after drug administration (p < 0.05), indicating an improvement in the condition earlier than in the double-dose PPI group. Moreover, in examinations concerning BMI and age, the HST group had a significantly higher improvement degree of ARD score in patients with BMI < 22 (p < 0.05) and aged < 65 years (p < 0.05) than the double-dose PPI group.

Conclusions

HST may be beneficial for patients with PPI-refractory GERD, particularly in non-obese and non-elderly patients with dyspepsia symptoms.

Keywords

GERD NERD Hangeshashinto Proton pump inhibitor 

Notes

Acknowledgements

Kazuhide Higuchi and Toshihisa Takeuchi contributed to the concept and design of the study. We are grateful to the GERD-4 Study Group (Tetsuo Arakawa, Kazuma Fujimoto, Motoyasu Kusano, Kazunari Tominaga) for providing a useful reference for the design of this study. All authors approved the final version of the manuscript. We thank Nouvelle Place Inc. Tokyo, Japan, for their great support on data management and statistical analysis. We would like to thank Editage (www.editage.jp) for English language editing. We thank Chinatsu Saito, Yoshinori Ozaki of Tsumura Co., Ltd. Tokyo, Japan, who received information on hangeshashinto for research planning. This research was funded by Tsumura Co., Ltd. Tokyo, Japan.

Compliance with ethical standards

Conflict of interest

Kazuhide Higuchi has received honoraria from Tsumura Co,. Ltd.

Supplementary material

535_2019_1588_MOESM1_ESM.docx (23 kb)
Supplementary material 1 (DOCX 23 kb)
535_2019_1588_MOESM2_ESM.docx (16 kb)
Supplementary material 2 (DOCX 16 kb)
535_2019_1588_MOESM3_ESM.docx (22 kb)
Supplementary material 3 (DOCX 21 kb)
535_2019_1588_MOESM4_ESM.docx (18 kb)
Supplementary material 4 (DOCX 17 kb)

References

  1. 1.
    Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.CrossRefGoogle Scholar
  2. 2.
    Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751–67.CrossRefGoogle Scholar
  3. 3.
    Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518–34.CrossRefGoogle Scholar
  4. 4.
    Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease—where next? Aliment Pharmacol Ther. 2005;22:79–94.CrossRefGoogle Scholar
  5. 5.
    Iwakiri K, Kawami N, Sano H, et al. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring. J Gastroenterol. 2009;44:708–12.CrossRefGoogle Scholar
  6. 6.
    G-PRIDE Study Group, Tominaga K, Kato M, et al. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study. J Gastroenterol. 2014;49:1392–405.CrossRefGoogle Scholar
  7. 7.
    Sakata Y, Tominaga K, Kato M, et al. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito. BMC Gastroenterol. 2014;14:116.CrossRefGoogle Scholar
  8. 8.
    Harasawa S, Miwa T. The efficacy of Hangeshashinto on gastric motility disorders. Prog Med. 1993;13:2533–9 (Japanese).Google Scholar
  9. 9.
    Gochi A, Hirose S, Sato K, et al. The effect of Hange-shashin-to and Rikkunshi-to against the digestive symptoms after gastrectomy. Jpn J Gastroenterol Surg. 1995;28:961–5 (Japanese).CrossRefGoogle Scholar
  10. 10.
    Aoyama T, Nishikawa K, Takiguchi N, et al. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 2014;73:1047–54.CrossRefGoogle Scholar
  11. 11.
    Matsuda C, Munemoto Y, Mishima H, et al. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 2015;76:97–103.CrossRefGoogle Scholar
  12. 12.
    Yamaguchi O, Kawashima A, Shiono A, et al. Hange-Shashin-to for preventing diarrhea during afatinib therapy. Gan To Kagaku Ryoho. 2015;42:581–3 (Japanese).PubMedGoogle Scholar
  13. 13.
    Hoshi N, Kofunato Y, Yashima R, et al. Treating side effects of FOLFIRINOX–a study of the effect of Hange-shashin-to on preventing diarrhea. Gan To Kagaku Ryoho. 2015;42:2364–6 (Japanese).PubMedGoogle Scholar
  14. 14.
    Fukamachi H, Matsumoto C, Omiya Y, et al. Effects of Hangeshashinto on growth of oral microorganisms. Evid Based Complement Altern Med. 2015;2015:1–6.CrossRefGoogle Scholar
  15. 15.
    Kase Y, Hayakawa T, Ishige A, et al. The Effects of Hange-shashin-to on the content of prostaglandin E2 and water absorption in the large intestine of rats. Biol Pharm Bull. 1997;20:954–7.CrossRefGoogle Scholar
  16. 16.
    Takeuchi T, Kawaguchi S, Takahashi Y, et al. Su1132 efficacy of Hange-shashinto on gastrointestinal symptoms in patients with gastroesophageal reflux disease refractory to proton pump inhibitor therapy. Gastroenterology. 2016;150:S478.CrossRefGoogle Scholar
  17. 17.
    Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888–91.CrossRefGoogle Scholar
  18. 18.
    Kusano M, Shimoyama Y, Kawamura O, et al. Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. Dig Dis Sci. 2007;52:1673–7.CrossRefGoogle Scholar
  19. 19.
    Svedlund J, Sjödin I, Dotevall G. GSRS—a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129–34.CrossRefGoogle Scholar
  20. 20.
    Tominaga K, Iwakiri R, Fujimoto K, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47:284–92.CrossRefGoogle Scholar
  21. 21.
    Domingues G, Moraes-Filho JPP, Fass R. Refractory heartburn: a challenging problem in clinical practice. Dig Dis Sci. 2018;63:577–82.CrossRefGoogle Scholar
  22. 22.
    Altomare A, Guarino MP, Cocca S, et al. Gastroesophageal reflux disease: update on inflammation and symptom perception. World J Gastroenterol. 2013;19:6523–8.CrossRefGoogle Scholar
  23. 23.
    Kondo T, Oshima T, Tomita T, et al. Prostaglandin E 2 mediates acid-induced heartburn in healthy volunteers. Am J Physiol-Gastrointest Liver Physiol. 2013;304:G568–73.CrossRefGoogle Scholar
  24. 24.
    Kondo T, Oshima T, Tomita T, et al. The nonsteroidal anti-inflammatory drug diclofenac reduces acid-induced heartburn symptoms in healthy volunteers. Clin Gastroenterol Hepatol. 2015;13(1249–1255):e1.Google Scholar
  25. 25.
    Kondo T, Sei H, Yamasaki T, et al. A novel prostanoid EP1 receptor antagonist, ONO-8539, reduces acid-induced heartburn symptoms in healthy male volunteers: a randomized clinical trial. J Gastroenterol. 2017;52:1081–9.CrossRefGoogle Scholar
  26. 26.
    Kono T, Kaneko A, Matsumoto C, et al. Multitargeted effects of hangeshashinto for treatment of chemotherapy-induced oral mucositis on inducible prostaglandin e2 production in human oral keratinocytes. Integr Cancer Ther. 2014;13:435–45.CrossRefGoogle Scholar
  27. 27.
    Takasuna K, Hagiwara T, Watanabe K, et al. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother Pharmacol. 2006;58:494–503.CrossRefGoogle Scholar
  28. 28.
    Miyashita T, Kono T, Matsui D, et al. Preventive effect of oral hangeshashinto (TJ-14) on the development of reflux-induced esophageal cancer. Surgery. 2018;164:49–55.CrossRefGoogle Scholar
  29. 29.
    Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176:172.CrossRefGoogle Scholar
  30. 30.
    Mössner J. The indications, applications, and risks of proton pump inhibitors. Dtsch Arztebl Int. 2016;113:477.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Dunbar KB, Agoston AT, Odze RD, et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA. 2016;315:2104–12.CrossRefGoogle Scholar
  32. 32.
    Ren LH, Chen WX, Qian LJ, et al. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20:2412–9.CrossRefGoogle Scholar
  33. 33.
    Miwa H, Inoue K, Ashida K, et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease—a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33:323–32.CrossRefGoogle Scholar
  34. 34.
    Takeuchi T, Takahashi Y, Kawaguchi S, et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor: Therapy of GERD and FD overlaps. J Gastroenterol Hepatol. 2018;33:623–30.CrossRefGoogle Scholar
  35. 35.
    Shah SL, Lacy BE, DiBaise JK, et al. The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy. Aliment Pharmacol Ther. 2015;42:1093–100.CrossRefGoogle Scholar
  36. 36.
    Utumi Y, Iseki E, Murayama N, et al. Effect of Rikkunshi-to on appetite loss found in elderly dementia patients: a preliminary study: rikkunshi-to and elderly dementia patients. Psychogeriatrics. 2011;11:34–9.CrossRefGoogle Scholar
  37. 37.
    Pilotto A, Franceschi M, Paris F. Recent advances in the treatment of GERD in the elderly: focus on proton pump inhibitors: treatment of GERD in the elderly. Int J Clin Pract. 2005;59:1204–9.CrossRefGoogle Scholar
  38. 38.
    Mantani N, Oka H, Watanabe T, et al. Incidence of liver injury related to kampo medicine containing Scutellaria baicalensis at our clinic. Kampo Med. 2017;68:377–81 (Japanese).CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  • Toshihisa Takeuchi
    • 1
    Email author
  • Hitoshi Hongo
    • 2
  • Tsuguhiro Kimura
    • 2
  • Yuichi Kojima
    • 1
  • Satoshi Harada
    • 3
  • Kazuhiro Ota
    • 3
  • Nozomi Takeuchi
    • 4
  • Takao Noguchi
    • 5
  • Takuya Inoue
    • 6
  • Mitsuyuki Murano
    • 7
  • Kazuhide Higuchi
    • 3
  1. 1.Osaka Medical College Hospital Endoscopy CenterTakatsukiJapan
  2. 2.Fujita Gastroenterology HospitalOsakaJapan
  3. 3.Department of Internal Medicine IIOsaka Medical College HospitalOsakaJapan
  4. 4.Settsu ClinicOsakaJapan
  5. 5.Noguchi ClinicOsakaJapan
  6. 6.Inoue Gastroenterology ClinicOsakaJapan
  7. 7.Murano ClinicOsakaJapan

Personalised recommendations